Good day to you! The sun is shining, the birds are singing, and the Pharmalot campus is buzzing with activity. We’re starting our day with a delicious cup of hot buttery rum coffee, sweetened with locally made honey. As we enjoy our caffeine fix, we’ve gathered some interesting news tidbits for you to peruse. So sit back, relax, and stay tuned for updates.
The Biden administration is taking action to address shortages of cancer drugs for children, as part of its efforts to reduce the nation’s cancer burden. The government is working on improving communication between hospitals, nonprofits, and wholesalers to prevent treatment disruptions for seven pediatric cancer drugs. Shortages of cancer medicines are a common issue that hospitals and patients face, often leading to delays or changes in care. The fragile supply chain for cheap, generic drugs like chemotherapies can exacerbate these shortages, prompting some hospitals to hoard supply or delay treatment.
In another development, a charter company working for Charles River Laboratories has been fined by Canadian authorities for improperly shipping long-tailed macaques into the country. This incident has sparked an investigation by officials responsible for overseeing the Convention on International Trade in Endangered Species (CITES), a treaty aimed at protecting endangered plants and animals from the perils of international trade. While it is unclear if the International Air Transportation Association regulations were violated, the CITES Secretariat is looking into the matter. Additionally, three members of the Canadian Parliament have requested an investigation into the shipments.
It’s crucial to ensure that endangered species are protected and that regulations governing their transportation are strictly adhered to. The implications of such incidents can have far-reaching consequences for biodiversity and conservation efforts. As the investigation unfolds, it will be interesting to see how authorities address any potential violations and ensure that such incidents are prevented in the future.
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. His insights and expertise in the field provide valuable perspectives on the latest developments and trends shaping the pharmaceutical landscape. Stay tuned for more updates and in-depth analysis from Ed and the Pharmalot team as we continue to bring you the latest news from the world of healthcare and pharmaceuticals.
